Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Jose Cuervo: Salida a bolsa
Jansat Mayench, Oriol; Carbonell López; Óscar; Rahnema Alavi, AhmadCaso F-975FinanzasLa salida a bolsa de Jose Cuervo (JC) en febrero de 2017 marcó todo un hito en el mundo del tequila por el hecho de ser la primera empresa tequilera del mundo en salir a bolsa. La salida de la empresa mexicana fue especialmente relevante porque se produjo meses después de la llegada a la Casa Blanca del presidente Donald Trump, que había criticado al Gobierno mexicano y había planteado la necesidad de renegociar el Tratado de Libre Comercio de Am...Desde 8,20 €
-
NatuRi Corporation
Higgins, Robert F.; Fuller, Virginia A.Caso HBS-807027-EFinanzasNatuRi Corp. was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from the byproducts of rice bran oil production. With operations split between Chennai, India and Boston, Massachusetts, NatuRi faced several challenges, including securing funding for the organization. NatuRi had captured the attention of at least four potential investors willing to offer an investment. Its managers were challenged to weigh their...Desde 8,20 €
-
Jose Cuervo: Going Public
Jansat Mayench, Oriol; Carbonell López; Óscar; Rahnema Alavi, AhmadCaso F-975-EFinanzasThe initial public offering of José Cuervo (JC) in February 2017 marked a milestone in the world of tequila, as the first tequila company in the world to go public. The listing of the Mexican company was especially relevant because it took place months after the arrival of President Donald Trump to the White House. He had criticized the Mexican government and the need to renegotiate the North American Free Trade Agreement (NAFTA). The listing led...Desde 8,20 €
-
U.S. Food and Drug Administration
Higgins, Robert F.; Hamermesh, Richard G.; Fuller, Virginia A.Caso HBS-807050-ELiderazgo y Dirección de personasDescribes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.Desde 8,20 €
-
Odyssey Healthcare
Higgins, Robert F.; Fuller, Virginia A.; Raffat, UmerCaso HBS-809052-EIniciativa emprendedoraIn January 2001, Dick Burnham, CEO of Odyssey Healthcare, and Odyssey's Board of Directors were considering selling the hospice care company to a larger provider or making an initial public offering (IPO). With 38 hospice locations in 21 states, Odyssey had been providing care to the terminally ill since its first location opened in 1996. Since then, the company had grown rapidly through a series of acquisitions, development of new hospice locati...Desde 8,20 €